Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Recruiting 6Completed 5Not yet recruiting 3Active not recruiting 2Unknown 1No longer available 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 1

Conditions

Lymphoma, Mantle-Cell 13Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Lymphoma, B-Cell, Marginal Zone 8Waldenstrom Macroglobulinemia 6Lymphoma 6Recurrence 4Lymphoma, B-Cell 4Neoplasms 2Leukemia 2Lymphoma, Non-Hodgkin 1Lymphohistiocytosis, Hemophagocytic 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Rituximab 7zanubrutinib 6venetoclax 4ibrutinib 3Dexamethasone 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2Blood Specimen Collection 2Biopsy 2Bendamustine Hydrochloride 2pirtobrutinib 1obinutuzumab 1Positron-Emission Tomography 1Lenalidomide 1Exercise 1Diet 1CT-P10 1Bortezomib 1ARQ531 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Waldenstrom Macroglobulinemia × zanubrutinib × Clear all
NCT04840602 2026-06-03

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

National Cancer Institute (NCI)

Phase 2 Recruiting
92 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT06561347 2026-03-31

ZEBRA

Massachusetts General Hospital

Phase 2 Recruiting
55 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT05640102 2026-03-04

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

BeOne Medicines

Recruiting
111 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT07169331 2025-12-19

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

BeOne Medicines

Phase 4 Recruiting
18 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT05326308 2025-09-23

ARIADNE

iOMEDICO AG

Recruiting
705 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT05914662 2024-08-28

ZBR

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
42 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡